Abstract
Urine is processed with a simple C18 solid-phase extraction (SPE) and reconstituted in mobile phase. The liquid chromatography system (LC) injects 10 μL of extracted sample onto a reverse-phase LC column for gradient analysis with ammonium formate/acetonitrile mobile phases. Drugs in the column eluent become charged in the ion source using positive electrospray ionization (ESI). Pseudomolecular ions (M + H) are analyzed by a hybrid triple-quadrupole linear ion trap (QqQ and QqLIT) mass spectrometer using an SRM-IDA-EPI acquisition. An initial 125 compound selected ion monitoring (SRM) survey scan (triple quadrupole or QqQ mode) is processed by the information-dependent acquisition (IDA) algorithm. The IDA algorithm selects SRM signals from the survey scan with a peak height above the threshold (the three most abundant SRM signals above 1000 cps) to define precursor ions for subsequent dependent scanning. In the dependent QqLIT scan(s), selected precursor ion(s) are passed through the first quadrupole (Q1), fragmented with three different collision energies in the collision cell (Q2 or q), and product ions are collected in the third quadrupole (Q3), now operating as a linear ion trap (LIT). The ions are scanned out of the LIT in a mass dependent manner to produce a full-scan product ion spectrum (m/z 50–700) defined as an Enhanced (meaning acquired in LIT mode) Product Ion (EPI) spectrum (Mueller et al., Rapid Commun Mass Spectrom 19:1332–1338, 2005). Each EPI spectrum is linked to its precursor ion and to the associated SRM peak from the survey scan. EPI spectra are automatically searched against a 125 drug library of reference EPI spectra for identification. When the duty cycle is complete (one survey scan of 125 SRMs plus 0–3 dependent IDA-EPI scans) the mass spectrometer begins another survey scan of the 125 SRMs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Maurer HH (2006) Hyphenated mass spectrometric techniques-indispensable tools in clinical and forensic toxicology and in doping control. J Mass Spectrom 4:1399–1413, Review
Marquet P (2002) Is LC-MS suitable for a comprehensive screening of drugs and poisons in clinical toxicology? Ther Drug Monit 24:125–133, Review
Saint-Marcoux F, Lachâtre G, Marquet P (2003) Evaluation of an improved general unknown screening procedure using liquid chromatography-electrospray-mass spectrometry by comparison with gas chromatography and high-performance liquid-chromatography—diode array detection. J Am Soc Mass Spectrom 14:14–22
Sauvage FL, Saint-Marcoux F, Duretz B, Deporte D, Lachâtre G, Marquet P (2006) Screening of drugs and toxic compounds with liquid chromatography-linear ion trap tandem mass spectrometry. Clin Chem 52:1735–1742
Lynch KL, Breaud AR, Vandenberghe H et al (2010) Performance evaluation of three liquid chromatography mass spectrometry methods for broad spectrum drug screening. Clin Chim Acta 411:1474–1481
Mueller CA, Weinmann W, Dresen S, Schreiber A, Gergov M (2005) Development of a multi-target screening analysis for 301 drugs using a QTrap liquid chromatography/tandem mass spectrometry system and automated library searching. Rapid Commun Mass Spectrom 19:1332–1338
Arhard K, Gottshcall A, Pitterl F et al (2015) Applying ‘Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass Spectra’ (SWATH) for systematic toxicological analysis with liquid chromatography-high-resolution tandem mass spectrometry. Anal Bioanal Chem 407:405–414
Roemmelt AT, Steuer AE, Poetzsch M et al (2014) Liquid Chromatography, in combination with a quadrupole Time-of-Flight instrument (LC QTOF), with sequential windowed acquisition of all theoretical fragment ion mass spectra (SWATH) acquisition: systematic studies on its use for screenings in clinical and forensic toxicology and comparison with information-dependent acquisition (IDA). Anal Chem 86:11742–11749
Chase D et al (2007) Mass spectrometry in the clinical laboratory: general principles and guidance. Approved Guideline C50-A. Clinical and Laboratory Standards Institute, Wayne, PA
Acknowledgements
The author would like to thank Julia Drees, Ph.D., Scientific Director, and Judy Chang, M.Sc., Scientific Director, from Kaiser TPMG Regional Laboratories, Berkeley, CA, and Christopher Borton, Ph.D., from AB Sciex for their contributions to the development of this method, expert advice, and fruitful collaboration.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Stone, J. (2016). Broad-Spectrum Drug Screening Using Liquid Chromatography-Hybrid Triple-Quadrupole Linear Ion Trap Mass Spectrometry. In: Garg, U. (eds) Clinical Applications of Mass Spectrometry in Drug Analysis. Methods in Molecular Biology, vol 1383. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3252-8_16
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3252-8_16
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3251-1
Online ISBN: 978-1-4939-3252-8
eBook Packages: Springer Protocols